Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Josep Tabernero

Associate Professor Faculty of Medicine

Universitat de Vic - Universitat Central de Catalunya

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Cell Biology Cell Biology professors in Spain

Articles (21)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2020

Collaborators (13)

Scott E. Kopetz

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Gunnar Folprecht

Unit Chair Medical Oncology

University Hospital Carl Gustav Carus

GERMANY

View details

Taroh Satoh

Professor

Osaka University Hospital

JAPAN

View details

Keun-Wook Lee

Professor

Seoul National University Hospital

SOUTH KOREA

View details

Sebastian Stintzing

Professor

Charité - Universitätsmedizin Berlin

GERMANY

View details

Hans Prenen

Antwerp University Hospital

BELGIUM

View details

Hidekazu Hirano

Keio University School of Medicine

JAPAN

View details

Ignacio Melero

Kidani Professor of Cancer Immuno-Therapeutics

University of Oxford

UNITED KINGDOM

View details

Yohann Loriot

Institut Gustave Roussy

FRANCE

View details

Joon Oh Park

Sungkyunkwan University School of Medicine

SOUTH KOREA

View details

Sara Lonardi

Head of Dept

Istituto Oncologico Veneto

ITALY

View details

Navid Hafez

Angeles Clinic and Research Institute

UNITED STATES

View details

Eric Van Cutsem

BELGIUM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Josep Tabernero

Research Interests

Explore related searches

Articles (21)

Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up

Erdafitinib in Patients with FGFR-altered Advanced or Metastatic Cholangiocarcinoma

A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3

Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair–Deficient/Microsatellite Instability Colorectal Cancers

Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors

Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial

Rechallenge With Anti-Human Epidermal Growth Factor Receptor 2 Therapy Guided by Liquid Biopsy in HER2 -Amplified Metastatic Colorectal Cancer

Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E–mutant metastatic colorectal cancer

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications

Drug Cost Avoidance Resulting from Participation in Clinical Trials: A 10-Year Retrospective Analysis of Cancer Patients with Solid Tumors

Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers

Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications

Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells

Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond

The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls

Collaborators (13)

Scott E. Kopetz

Gunnar Folprecht

Taroh Satoh

Keun-Wook Lee

Sebastian Stintzing

Hans Prenen

Hidekazu Hirano

Ignacio Melero

Yohann Loriot

Joon Oh Park

Sara Lonardi

Navid Hafez

Eric Van Cutsem

Make your next move.